

November 2011

EP24-A2

Assessment of the Diagnostic Accuracy of Laboratory Tests Using Receiver Operating Characteristic Curves; Approved Guideline—Second Edition

This document provides a protocol for evaluating the accuracy of a test to discriminate between two subclasses of subjects when there is some clinically relevant reason to separate them. In addition to the use of receiver operating characteristic curves and the comparison of two curves, the document emphasizes the importance of defining the question, selecting the sample group, and determining the "true" clinical state.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

Clinical and Laboratory Standards Institute Setting the standard for quality in clinical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are addressed according to the consensus process by a committee of experts.

Appeals Process

If it is believed that an objection has not been adequately addressed, the process for appeals is documented in the CLSI Administrative Procedures.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For further information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute 950 West Valley Road, Suite 2500 Wayne, PA 19087 USA P: 610.688.0100 F: 610.688.0700 www.clsi.org standard@clsi.org

ISBN 1-56238-777-4 (Print)	EP24-A2
ISBN 1-56238-778-2 (Electronic)	Vol. 31 No. 23
ISSN 1558-6502 (Print)	Replaces GP10-A
ISSN 2162-2914 (Electronic)	Vol. 15 No. 19

Assessment of the Diagnostic Accuracy of Laboratory Tests Using Receiver Operating Characteristic Curves; Approved Guideline— Second Edition

Volume 31 Number 23

Martin H. Kroll, MD Bipasa Biswas Jeffrey R. Budd, PhD Paul Durham, MA Robert T. Gorman, PhD Thomas E. Gwise, PhD Abdel-Baset Halim, PharmD, PhD, DABCC Aristides T. Hatjimihail, MD, PhD Jørgen Hilden, MD Kyunghee Song, PhD

Abstract

Clinical and Laboratory Standards Institute document EP24-A2—Assessment of the Diagnostic Accuracy of Laboratory Tests Using Receiver Operating Characteristic Curves; Approved Guideline—Second Edition provides guidance for laboratorians and manufacturers who assess clinical test accuracy. It is not a recipe; rather, it is a set of concepts to be used to design an assessment of test performance or to interpret data generated by others. In addition to the use of ROC curves and comparison of two curves, the document emphasizes the importance of defining the question, selecting a sample group, and determining the "true" clinical state. The statistical data generated can be useful whether one is considering replacing an existing test, creating or adding a new test, or eliminating a current test.

Clinical and Laboratory Standards Institute (CLSI). Assessment of the Diagnostic Accuracy of Laboratory Tests Using Receiver Operating Characteristic Curves; Approved Guideline—Second Edition. CLSI document EP24-A2 (ISBN 1-56238-777-4 [Print]; ISBN 1-56238-778-2 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2011.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-mail: customerservice@clsi.org; Website: www.clsi.org.



Number 23

EP24-A2

Copyright [©]2011 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation

CLSI. Assessment of the Diagnostic Accuracy of Laboratory Tests Using Receiver Operating Characteristic Curves; Approved Guideline—Second Edition. CLSI document EP24-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.

Proposed Guideline March 1987

Tentative Guideline December 1993

Approved Guideline December 1995

Approved Guideline—Second Edition

November 2011

ISBN 1-56238-777-4 (Print) ISBN 1-56238-778-2 (Electronic) ISSN 1558-6502 (Print) ISSN 2162-2914 (Electronic)

Volume 31

Committee Membership

Consensus Committee on Evaluation Protocols

Greg Cooper, CLS, MHA Chairholder W. Gregory Cooper LLC Denton, Texas, USA

James F. Pierson-Perry Vice-Chairholder Siemens Healthcare Diagnostics Newark, Delaware, USA

J. Rex Astles, PhD, FACB, DABCC Centers for Disease Control and Prevention Atlanta, Georgia, USA Jeffrey R. Budd, PhD Beckman Coulter Chaska, Minnesota, USA

Jonathan Guy Middle, PhD University Hospital Birmingham NHS Trust Birmingham, United Kingdom Mitchell G. Scott, PhD Washington University School of Medicine St. Louis, Missouri, USA

Lakshmi Vishnuvajjala, PhD FDA Center for Devices and Radiological Health Silver Spring, Maryland, USA

Document Development Committee on Assessment of Diagnostic Accuracy of Laboratory Tests Using ROC Curves

Martin H. Kroll, MD Chairholder Boston Medical Center Boston, Massachusetts, USA

Jeffrey R. Budd, PhD Beckman Coulter Chaska, Minnesota, USA

Robert T. Gorman, PhD Siemens Healthcare Diagnostics Inc. Newark, Delaware, USA Jørgen Hilden, MD University of Copenhagen Copenhagen, Denmark

Kyunghee Song, PhD FDA Center for Devices and Radiological Health Silver Spring, Maryland, USA

Staff

Clinical and Laboratory Standards Institute Wayne, Pennsylvania, USA Luann Ochs, MS Vice President, Standards Development

Ron S. Quicho Staff Liaison

Patrice E. Polgar Project Manager

Megan P. Larrisey, MA *Editor*

Acknowledgment

CLSI and the Consensus Committee on Evaluation Protocols gratefully acknowledge the following individuals for their help in preparing this document:

Bipasa Biswas FDA Center for Devices and Radiological Health Silver Spring, Maryland, USA

Paul Durham, MA Culver City, California Thomas E. Gwise, PhD FDA Center for Drug Evaluation and Research Silver Spring, Maryland, USA

Abdel-Baset Halim, PharmD, PhD, DABCC Daiichi Sankyo Pharma Development Edison, New Jersey, USA

Aristides T. Hatjimihail, MD, PhD Hellenic Complex Systems Laboratory Drama, Greece

EP24-A2

Number 23

EP24-A2

volume 51	Vol	lume	31	
-----------	-----	------	----	--

Contents

Abstra	.ct		i		
Comm	ittee Me	embership	iii		
Forewo	ord		vii		
1	Scope.		1		
2	Introduction1				
3	Standard Precautions				
4	Terminology2				
	4.1 4.2 4.3	A Note on Terminology Definitions Abbreviations and Acronyms	2 3 5		
5	Design	ning the Basic Evaluation Study	5		
	5.1 5.2 5.3 5.4	Define the Clinical Question Select a Statistically Valid, Representative Study Sample Establish the "True" Clinical State of Each Subject Test the Study Subjects	7 7 9 10		
6	Constr	ruction of a Receiver Operating Characteristic Curve	11		
	6.1 6.2 6.3	Assess the Diagnostic Accuracy of the Test Generating the Receiver Operating Characteristic Curve: Ties Construction of the Receiver Operating Characteristic Curve When the Quantification Range Is Restricted	11 16 17		
7	Interpr	retation	17		
	7.1 7.2	Relating the Receiver Operating Characteristic Curve to Sensitivity and Specificity Area Under a Receiver Operating Characteristic Curve	18		
8	Applic	cation of Receiver Operating Characteristic Curves	28		
Refere	nces		30		
Appen	dix A. E	Effect of Measurement Uncertainty on Receiver Operating Characteristic Curves.	32		
Appen Practic	dix B. C cal Appli	Cumulative Distribution Analysis Plots: Their Nature, Construction, and ication	35		
Appen	dix C. R	Receiver Operating Characteristic Curve Areas and Rank-Sum Statistics	38		
Appen	dix D. A	A Receiver Operating Characteristic Curve Comparison Example	40		
The Qu	uality M	anagement System Approach	44		
Related	d CLSI I	Reference Materials	45		

Number 23

EP24-A2

Volume 31

EP24-A2

Foreword

Laboratorians, investigators, *in vitro* diagnostic manufacturers, and clinicians are often interested in how well a test performs clinically. This is true whether considering replacing an existing test with a newer one, adding a new test to the laboratory's menu, eliminating tests where possible, or evaluating the diagnostic power of a laboratory test relative to another clinical or diagnostic tool. This project was originally intended to make recommendations about assessing the clinical performance of diagnostic tests. The concepts of Swets and Pickett¹ were adopted, whereby clinical performance is divided into (1) a discriminatory or diagnostic element (diagnostic accuracy) and (2) a decision or efficacy element. Laboratory tests are ordered to help answer questions about patient management. How much help an individual test result provides is variable and, in any case, a highly complicated issue. Management decisions and strategies are complex activities that require the physician to consider probabilities of disease, quality of the data available, effectiveness of various treatment/management alternatives, probability of outcomes, and value (and cost) of outcomes to the patient. Many types of clinical data (including laboratory results) are usually integrated into a complex decision-making process. Most often, a single laboratory test result is not the sole basis for a diagnosis or a patient-management decision.

Therefore, some have criticized the practice of evaluating the diagnostic performance of a test as if it were used alone. However, each clinical tool (eg, a clinical laboratory test, an electroencephalogram, an electrocardiogram, a nuclide scan, an X-ray, a biopsy, a pulmonary function test, or a sonogram) is meant to make some definable discrimination. It is important to know just how inherently accurate each test is as a diagnostic discriminator. *Note that assessing diagnostic accuracy, without engaging in comprehensive clinical decision analysis, is a valid and useful activity for the clinical laboratory*. Diagnostic accuracy is the most fundamental characteristic of the test itself as a classification device; it measures the ability of the test to discriminate among alternative states of health. In the simplest form, this property is the ability to distinguish between just two states of health or circumstances. Sometimes this involves distinguishing health from disease; other times it might involve distinguishing between benign and malignant disease, categorizing subjects as responding to therapy vs those not responding, or predicting who will become ill vs who will not. This ability to distinguish or discriminate between two states among subjects is a property of the test itself.

Indeed, the ability of the test to distinguish between the relevant alternative states or conditions of the subject (ie, diagnostic accuracy) is the most basic property of a laboratory test as a device to help in decision making. Note that this basic property cannot be separated from the clinical problem being addressed and the spectrum effect of the mix of subject states on which the test system is based. This property is the place to start when assessing the value of a test in the patient-management process.

Exploration of the usefulness of medical information, such as test data, involves a number of factors or parameters that are not properties of the test system; rather, they are properties of the circumstances of the clinical application. These include the probability or prevalence of disease, the possible clinical outcomes and the relative values of diagnostic outcomes, the costs to the patient (and others) of incorrect information (false-positive and false-negative classifications), and the costs and benefits of various treatment options. These characteristics or properties form the context in which test information is used, but are not properties of the test system. These factors interact with test results to affect the usefulness of the test, but do not affect test accuracy.

In summary, diagnostic accuracy is defined as the basic ability to discriminate between two subclasses of subjects when there is some clinically relevant reason to separate them. This concept of diagnostic accuracy refers to the quality of the information (classification) provided by the test, which should be distinguished from the practical usefulness of the information.¹ Both are aspects of test performance. The assessment of diagnostic accuracy is the place to start in evaluating test performance. If a test cannot discriminate between clinically relevant subclasses of subjects, then there is little incentive to further explore a possible clinical role. If, on the other hand, a test does exhibit a substantial ability to

Number 23

EP24-A2

discriminate, then by examining the degree of accuracy of the test and/or by comparing its accuracy to that of other tests, one can decide whether to delve into a more complex assessment of its role in patient management (decision analysis). This document addresses the assessment of diagnostic accuracy but not the analysis of usefulness or the role of the test in the patient-management process.

In this second edition of the guideline, the document development committee has provided more details on the construction and interpretation of receiver operating characteristic (ROC) curves. Many more examples are included to help the reader assess an individual curve and its associated area under the curve, as well as to compare two curves. Sample size calculations are provided for the first time.

NOTE: Although a step-by-step technique for generating ROC curves has been presented in EP24, it is assumed that most users of this guideline will access commercially available software for this task.

Key Words

Area under the curve, diagnostic accuracy, false-negative fraction, false-positive fraction, medical decision level, receiver operating characteristic curve, sensitivity, specificity, true-negative fraction, true-positive fraction

Volume 31

EP24-A2

Assessment of the Diagnostic Accuracy of Laboratory Tests Using Receiver Operating Characteristic Curves; Approved Guideline—Second Edition

1 Scope

This guideline outlines the steps and principles of prospectively planned and retrospective studies to evaluate the intrinsic diagnostic accuracy of a clinical laboratory test, defined as its fundamental ability to discriminate correctly among alternative states of health. It is not intended to help determine how best to use a diagnostic test in clinical practice, but instead to determine how accurate a laboratory test is in terms of diagnostic sensitivity and specificity.

Receiver operating characteristic (ROC) curve methodology arose in response to needs in electronic signal detection and problems with radar in the early 1950s.² It is derived from conditional probabilities, as originally formulated by Bayes.³ This guideline aims to define ROC curves and to explain how to design, construct, interpret, and apply the information from ROC studies to evaluate diagnostic tests. For simplicity, only continuous scales, such as those typical for *in vitro* diagnostic tests, are discussed. The clinical condition that the test is intended to detect must be verifiable through some means other than the test under investigation. In other words, there must be an independent clinical reference standard against which one can compare the test. By selecting cutoffs between positive and negative diagnoses along the continuous scale of the test, the diagnostic outcomes for these decision levels are compared to the true clinical condition, which, in turn, generates the ROC curve.

This guideline will be of value to a wide variety of possible users, including:

- Investigators who are developing new tests for specific applications
- Manufacturers of reagents and devices for performing tests who are interested in assessing or validating test performance in terms of diagnostic accuracy
- Regulatory agencies interested in establishing requirements for claims related to diagnostic accuracy
- Clinical laboratorians who are reviewing data or the literature, and/or generating their own data, to make decisions about which tests to employ in their laboratories
- Health care or scientific workers interested in critical evaluation of data being presented on clinical test performance

2 Introduction

An ROC curve provides the following advantageous properties:

- It visually displays the performance of one or more diagnostic markers or tests across the entire measuring interval.
- By plotting unitless values (sensitivity vs specificity or sensitivity vs 1 specificity), one can compare the diagnostic performance of two or more diagnostic markers or tests regardless of:
 - Units of expression of different markers or tools (eg, mg/dL, mmol/L, U/L)
 - Type of diagnostic test (eg, a clinical laboratory test, pulmonary function test, radiography)
 - Type of biological sample analyzed (eg, serum vs urine, saliva vs blood)